Correct Answer: C. Increase in CRP increases the risk of Ml/stroke
The table demonstrates a dose-response relationship between CRP levels and cardiovascular risk, which is the hallmark of a true causal association in epidemiology. As CRP quintiles increase from 1 (0.1–1 mg/L) to 5 (4.1–5 mg/L), the relative risk progressively rises from 1.0 to 2.8. This monotonic increase in RR across exposure categories is a key criterion for establishing biological plausibility and causality (Bradford Hill criteria). In Indian populations, elevated CRP is recognized as an independent predictor of acute coronary syndrome and stroke risk, particularly in the context of metabolic syndrome and diabetes prevalence. The baseline RR of 1.0 in quintile 1 serves as the reference category; individuals in this lowest CRP stratum have the lowest cardiovascular event risk. The progressive elevation (1.3 → 1.7 → 2.1 → 2.8) indicates that each increment in CRP concentration is associated with proportionally higher risk, supporting a causal gradient. This is consistent with CRP's role as both a marker of systemic inflammation and a direct contributor to atherothrombotic pathology.
Why the other options are wrong
A. CRP has no association with risk of MI/stroke — This is wrong because the table explicitly shows a clear dose-response gradient in relative risk across CRP quintiles (1.0 → 2.8). The progressive increase in RR values directly contradicts the null hypothesis of no association. This option represents a misreading of the epidemiological data and ignores the monotonic trend, which is the strongest evidence for association in observational studies. B. In quintile 1, there is no risk of MI/stroke — This is wrong because quintile 1 (RR = 1.0) is the reference category, not an absolute zero-risk group. RR = 1.0 means the risk is equal to the baseline population average, not that MI/stroke cannot occur. Patients with low CRP still experience cardiovascular events; quintile 1 simply has the lowest relative risk compared to higher CRP groups. This is a common misinterpretation of relative risk in Indian medical exams. D. Increase in CRP decreases the risk of MI/stroke — This is wrong because it directly contradicts the observed data trend. The RR values increase monotonically with CRP quintiles, not decrease. This option may trap students who confuse CRP with protective factors (like HDL) or who misread the table direction. The inverse relationship proposed here has no biological or epidemiological support in the given data.
High-Yield Facts
- Dose-response relationship (RR 1.0 → 2.8 across quintiles) is the strongest evidence for causality in observational epidemiology and satisfies Bradford Hill criteria.
- CRP as a cardiovascular risk marker: In Indian populations, CRP >3 mg/L is associated with significantly elevated MI/stroke risk, independent of traditional risk factors.
- Reference category (RR = 1.0) in quintile 1 does NOT mean zero risk; it means baseline risk relative to which other groups are compared.
- Monotonic trend in RR across exposure categories (no dip or reversal) strengthens the inference of true association over confounding.
- CRP cutoff for risk stratification: Values >3 mg/L warrant aggressive cardiovascular risk reduction in Indian guidelines (IAP, ICMR recommendations).
Mnemonics
RR Trend = Causality Rising Relative Risk across exposure quintiles = Real Relationship. When RR climbs monotonically (1.0 → 1.3 → 1.7 → 2.1 → 2.8), suspect true causation, not confounding. Quintile 1 ≠ Zero Risk Quintile 1 is the Question-asker's trap: RR = 1.0 means 'baseline,' not 'no disease.' It's the reference, not a risk-free zone.
NBE Trap
NBE pairs "no association" (option A) with "no risk in quintile 1" (option B) to trap students who confuse reference categories with absence of disease, or who fail to recognize monotonic dose-response as evidence of association. The inverse relationship (option D) is a classic distractor for students who misread table trends.
Clinical Pearl
In Indian acute care settings, CRP >3 mg/L in acute coronary syndrome patients predicts higher in-hospital mortality and recurrent events. This table-based evidence justifies aggressive anti-inflammatory and lipid-lowering therapy in high-CRP patients, aligning with current IAP and ICMR cardiovascular risk reduction guidelines.
_Reference: Park's Textbook of Preventive and Social Medicine (Epidemiology chapter on causality and Bradford Hill criteria); Harrison's Principles of Internal Medicine Ch. 244 (Acute Coronary Syndromes)_